KeyBank National Association
PVLA icon

KeyBank National Association’s Palvella Therapeutics PVLA Stock Holding History

KeyBank National Association’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$456K Buy
2,983
+1,156
+63% +$140K ﹤0.01% 963
2026
Q1 		$228K Buy
+1,827
New +$191K ﹤0.01% 1142

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

KeyBank National Association's PVLA Position: Q2 2026 in Review

KeyBank National Association increased its Palvella Therapeutics (PVLA) stake by 63% in Q2 2026, buying an estimated $140K and bringing the position to 2,983 shares worth $456K. The position accounts for ﹤0.01% of the portfolio, ranked #963.

KeyBank National Association first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • KeyBank National Association held 2,983 shares of Palvella Therapeutics worth $456K as of Q2 2026.
  • KeyBank National Association bought 1,156 Palvella Therapeutics shares in Q2 2026, an estimated $140K.
  • Palvella Therapeutics made up ﹤0.01% of KeyBank National Association's portfolio in Q2 2026, its #963 holding.
  • KeyBank National Association first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on KeyBank National Association's 13F filing for Q2 2026, filed 28 Jul 2026.